Categories: News

Bavarian Nordic to Host First Quarter 2022 Results Conference Call and Webcast

COPENHAGEN, Denmark – May 4, 2022 – Bavarian Nordic A/S (OMX:  BAVA) will announce its 2022 first quarter results on Monday, May 9, 2022.

The management of Bavarian Nordic will host a conference call at 2:00 pm CEST (8:00 am EDT) on the same day to present the interim results followed by a Q&A session. A live and replay version of the call and relevant slides will be available at https://www.bavarian-nordic.com/investor/events.aspx?event=6388.

To join the Q&A session dial one of the following numbers and state the participant code 7179801: Denmark: +45 32 72 04 17, UK: +44 (0) 844 481 9752, USA: +1 646-741-3167

About Bavarian Nordic
Bavarian Nordic is a fully integrated vaccines company listed on the NASDAQ Copenhagen exchange and with operations in Europe and the USA. Our mission is to save and improve lives by unlocking the power of the immune system and we aspire to become one of the largest pure play vaccine companies by developing innovative life-saving vaccines, excelling in commercialization and being a best-in-class vaccine manufacturer. We are a global leader in smallpox vaccines and have been a long-term supplier to the U.S. Government of a non-replicating smallpox vaccine, which has been approved by the FDA, also for the protection against monkeypox. The vaccine is approved as a smallpox vaccine in Europe and Canada. Our commercial product portfolio furthermore contains market-leading vaccines against rabies and tick-borne encephalitis. Using our live virus vaccine platform technology, MVA-BN®, we have created a diverse portfolio of proprietary and partnered product candidates, including an Ebola vaccine, which is licensed to the Janssen Pharmaceutical Companies of Johnson & Johnson. We are also committed to the development of a next-generation COVID-19 vaccine and a vaccine against respiratory syncytial virus (RSV), which are both entering Phase 3 clinical trials in 2022. For more information visit www.bavarian-nordic.com.

Contacts
Europe: Rolf Sass Sørensen, Vice President Investor Relations & Communications. Tel: +45 61 77 47 43
U.S.: Graham Morrell, Paddock Circle Advisors (US), Tel: +1 781 686 9600

Staff

Recent Posts

KORU Medical Systems to Present Data Demonstrating 97% Adherence on Its Freedom Infusion System for Large Volume Subcutaneous Administration at NHIA 2024 Conference

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading…

18 mins ago

Pharma-Bio Serv Announces Results for the Quarter Ended January 31, 2024

DORADO, PUERTO RICO / ACCESSWIRE / March 18, 2024 / Pharma-Bio Serv, Inc. ("Pharma-Bio Serv"…

19 mins ago

West Island Brands Acquires Contract to Supply Bio Products Internationally

Toronto, Ontario--(Newsfile Corp. - March 18, 2024) - West Island Brands Inc. (CSE: WIB) (FSE:…

5 hours ago

NextGen Healthcare Chosen by United Medical Centers to Support Integrated Care Delivery in Communities at United States-Mexico Border

Growing Need for Integration Led FQHC to Select NextGen HealthcareREMOTE-FIRST COMPANY/EAGLE PASS, Texas--(BUSINESS WIRE)--#NextGenHealthcare--Driven by…

6 hours ago

The Assistance Fund Opens New Program for Heart Failure

Copay Assistance From The Assistance Fund Now Available for Eligible People Living With Heart FailureORLANDO,…

6 hours ago

US Med-Equip Earns CIO 100 Award for IT Innovation With New AI Solution Helping Clinicians Secure Medical Equipment on Demand

Life-Saving Equipment Delivered to Patients in Record Time, Lower Cost at Hospitals Using Award-Winning GoUSME…

6 hours ago